|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1-2
|
|
pubmed:dateCreated |
2008-3-31
|
|
pubmed:abstractText |
Irinotecan has been introduced to improve the treatment of small-cell lung cancer (SCLC). We conducted a trial involving a 3-week schedule of irinotecan combined with cisplatin (IP) to validate the efficacy and toxicity of this regimen in patients with previously untreated extensive-stage SCLC (ES-SCLC).
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
1423-0232
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
(c) 2008 S. Karger AG, Basel
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
73
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
76-80
|
|
pubmed:meshHeading |
pubmed-meshheading:18334853-Aged,
pubmed-meshheading:18334853-Antineoplastic Agents, Phytogenic,
pubmed-meshheading:18334853-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:18334853-Camptothecin,
pubmed-meshheading:18334853-Carcinoma, Small Cell,
pubmed-meshheading:18334853-Cisplatin,
pubmed-meshheading:18334853-Disease-Free Survival,
pubmed-meshheading:18334853-Drug Administration Schedule,
pubmed-meshheading:18334853-Female,
pubmed-meshheading:18334853-Follow-Up Studies,
pubmed-meshheading:18334853-Humans,
pubmed-meshheading:18334853-Infusions, Intravenous,
pubmed-meshheading:18334853-Lung Neoplasms,
pubmed-meshheading:18334853-Male,
pubmed-meshheading:18334853-Middle Aged,
pubmed-meshheading:18334853-Neoplasm Staging,
pubmed-meshheading:18334853-Neutropenia,
pubmed-meshheading:18334853-Survival Analysis,
pubmed-meshheading:18334853-Treatment Outcome
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Phase II study of a 3-week schedule of irinotecan combined with cisplatin in previously untreated extensive-stage small-cell lung cancer.
|
|
pubmed:affiliation |
Department of Internal Medicine, College of Medicine, Chungnam National University Hospital and Cancer Research Institute, Daejeon, South Korea.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial, Phase II
|
